Characteristics | European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium | Chinese Group on the Study of Severe Hepatitis B (COSSH) | Asian Pacific Association for the Study of the Liver (APASL) ACLF Research Consortium (AARC) | North American Consortium for the Study of End-stage Liver Disease (NACSELD) |
---|---|---|---|---|
Study type | Multicentre, prospective, observational study | Multicentre, prospective, observational study | Expert consensus report | Multicentre, prospective, observational study |
Main aetiology | Alcohol, HCV | HBV | HBV | Alcohol |
Precipitating events | Intrahepatic (alcoholic hepatitis), extrahepatic (infection, variceal haemorrhage), or both | Intrahepatic (HBV reactivation), extrahepatic (bacterial infection) or both | Intrahepatic | Intrahepatic, extrahepatic or both |
Population | Compensated and decompensated cirrhosis | HBV-related chronic liver disease | Chronic liver disease Compensated cirrhosis | Compensated and decompensated cirrhosis |
Criteria of Organ failure | Liver: total bilirubin ≥ 12 mg/dL; Kidney: creatinine ≥ 2 mg/dL or use of RRT; Coagulation: INR ≥ 2.5; Brain: West Haven grade 3–4 HE or use of mechanical ventilation due to HE; Circulation: Use of vasopressors; Respiration: PaO2/FiO2 ≤ 200 or SpO2/FiO2 ≤ 214, or use of mechanical ventilation not due to HE | Liver: Total bilirubin ≥ 12 mg/dL; Kidney: Creatinine ≥ 2 mg/dL or use of RRT; Coagulation: INR ≥ 2.5; Brain: West Haven grade 3–4 HE or use of mechanical ventilation due to HE; Circulation: Use of vasopressors; Respiration: PaO2/FiO2 ≤ 200 or SpO2/FiO2 ≤ 214, or use of mechanical ventilation not due to HE | Liver: Total bilirubin ≥ 5 mg/dL; Brain: clinical HE | Kidney: Use of dialysis or other form of RRT; Brain: HE Grade 3–4 in West Haven classification; Circulation: MAP < 60 mmHg or reduction of 40 mmHg in SBP from baseline, in spite of fluid resuscitation and adequate cardiac output; Respiration: Use of mechanical ventilation |
Criteria for the presence of ACLF and ACLF stratification | ACLF is divided into 3 grades of increasing severity Grade 1 includes 3 subgroups: (1) single kidney failure; (2) single liver, coagulation, circulatory or respiratory failure with either kidney dysfunction, brain dysfunction, or both; (3) single brain failure and kidney dysfunction; Grade 2: 2 organ failures; Grade 3: 3 or more organ failures | ACLF is divided into 3 grades of increasing severity Grade 1 includes 4 subgroups: (1) single kidney failure; (2) single liver failure and either INR ≥ 1.5, kidney dysfunction, brain dysfunction, or any combination of these alterations; (3) single coagulation, circulatory or respiratory failure with either kidney dysfunction, brain dysfunction, or both; (4) brain failure alone plus kidney dysfunction; Grade 2: 2 organ failures; Grade 3: 3 or more organ failures | Acute hepatic insult manifesting as jaundice (total bilirubin levels of 5 mg/dl or more) and coagulopathy (INR ≥ 1.5, or prothrombin activity < 40%) complicated within 4 weeks by clinical ascites, HE, or both The severity of ACLF is assessed using the AARC score Grade 1: 5–7 scores, Grade 2: 8–10 scores, Grade 3: 11–15 scores | Patients are stratified according to the number of organ failures 2, 3, or all 4 organ failures |
Prevalence of ACLF grade | Grade 1: 49% Grade 2: 35% Grade 3: 16% | Grade 1: 61% Grade 2: 33% Grade 3: 6% | / | 2 Organ failures: 43% 3 Organ failures: 41% 4 Organ failures: 16% |
Main organ failures | Kidney, Liver | Liver, Coagulation | Liver, Coagulation | Brain |
Short-term mortality rate of ACLF | By 28 days: Grade 1: 22% Grade 2: 32% Grade 3: 77% | By 28 days: Grade 1: 23% Grade 2: 61% Grade 3: 93% | By 28 days: Grade 1: 13% Grade 2: 45% Grade 3: 86% | By 30 days: 2 Organ failures: 49% 3 Organ failures: 64% 4 Organ failures: 77% |